Exact Sciences (EXAS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jul, 2026Opening remarks and agenda
Meeting called to order by the Chairman, with board members and key officers present.
Inspector of Election confirmed and agenda, rules of conduct, and Q&A procedures outlined.
Shareholder proposals
Three proposals presented: approval of merger agreement, advisory vote on executive compensation related to the merger, and potential adjournment to solicit more proxies.
Q&A with stakeholders
Stockholders could submit questions online, limited to one per person, with follow-up promised for unanswered questions.
Updates provided on regulatory approvals (expected completion before end of Q2 2026) and reference to SEC filings for merger-related litigation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Exact Sciences
- Multi-cancer early detection could cut late-stage cancer by 40% and mortality by 18%.EXAS
7th Annual Healthcare Symposium - International expansion accelerates with new products, offices, and integration with Abbott.EXASProxy Filing
- Record revenue, improved cash flow, and major merger plans mark a transformative year.EXASQ4 2025
- Merger with Abbott at $105 per share prompts supplemental disclosures and litigation response.EXASProxy Filing
- Q2 revenue up 12% to $699M; record test volumes and raised EBITDA guidance.EXASQ2 2024
- Cologuard Plus and a robust pipeline position the company for sustained growth and market leadership.EXASJefferies Global Healthcare Conference
- All proposals passed, with director elections, auditor ratification, and no shareholder questions.EXASAGM 2024
- Cologuard Plus, automation, and global expansion fuel strong growth and margin gains.EXASGoldman Sachs 45th Annual Global Healthcare Conference
- Growth driven by innovation, digital integration, and organizational agility, with guidance reaffirmed.EXASThe 44th Annual William Blair Growth Stock Conference